Case Reports
Vol. 6 (2016)
https://doi.org/10.4081/cdr.6.5815

Aromatase inhibitor therapy in a cystic fibrosis patient with thoracic endometriosis

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 17 February 2016
Published: 8 November 2016
1392
Views
693
Downloads
Thoracic endometriosis, Aromatase inhibitor, Cystic fibrosis

Authors

Olga T. Filippova
filippo@mail.amc.edu
Albany Medical Center, Albany, NY, United States.
Heidi E. Godoy
Albany Medical Center, Albany, NY; Women’s Cancer Care Associates, Albany, NY, United States.
Patrick F. Timmins III
Albany Medical Center, Albany, NY; Women’s Cancer Care Associates, Albany, NY, United States.
The thoracic cavity is the number one site for extrapelvic endometriosis, with catamenial pneumothorax as the most common presenting symptom. Its treatment algorithm is similar to the one for pelvic endometriosis, with the goal of inducing a hypoestrogenic state. However, if medical treatment fails, lung resection may be the only option. We present a case of a 44-year-old female with cystic fibrosis and known pelvic endometriosis, who was diagnosed with thoracic endometriosis after presenting with catamenial hemoptysis. After having a recurrence more than four years after a bilateral salpingo-oophorectomy, she was started on aromatase inhibitor (AI) therapy to avoid lung resection. Such therapy with an AI successfully treated recurrent thoracic endometriosis in a patient with cystic fibrosis, i.e. not an ideal candidate for lung resection.

Downloads

Download data is not yet available.

How to Cite



Aromatase inhibitor therapy in a cystic fibrosis patient with thoracic endometriosis. (2016). Chest Disease Reports, 6(1). https://doi.org/10.4081/cdr.6.5815

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.